On May 8, AstraZeneca's new small molecule drug plant in Wuxi officially started construction. The new plant has a total investment of 475 million US dollars and covers an area of about 30,000 square meters. It will be equipped with two cutting-edge tablet continuous manufacturing process equipment and seven sustainable drug packaging production lines. It mainly produces innovative cardiovascular drugs in AstraZeneca's research pipeline. It is expected to be put into operation in the fourth quarter of 2028. This is a further deepening of AstraZeneca's supply chain layout in China following the completion of the first phase of the construction of the Qingdao Inhalation Aerosol Production and Supply Base last month.

Zhitongcaijing · 5d ago
On May 8, AstraZeneca's new small molecule drug plant in Wuxi officially started construction. The new plant has a total investment of 475 million US dollars and covers an area of about 30,000 square meters. It will be equipped with two cutting-edge tablet continuous manufacturing process equipment and seven sustainable drug packaging production lines. It mainly produces innovative cardiovascular drugs in AstraZeneca's research pipeline. It is expected to be put into operation in the fourth quarter of 2028. This is a further deepening of AstraZeneca's supply chain layout in China following the completion of the first phase of the construction of the Qingdao Inhalation Aerosol Production and Supply Base last month.